335 related articles for article (PubMed ID: 31113863)
21. The tumor suppressor protein p53 functions similarly to p63 and p73 in activating transcription in vitro.
Mondal N; Parvin JD
Cancer Biol Ther; 2005 Apr; 4(4):414-8. PubMed ID: 15846087
[TBL] [Abstract][Full Text] [Related]
22. Combinatorial control of the bradykinin B2 receptor promoter by p53, CREB, KLF-4, and CBP: implications for terminal nephron differentiation.
Saifudeen Z; Dipp S; Fan H; El-Dahr SS
Am J Physiol Renal Physiol; 2005 May; 288(5):F899-909. PubMed ID: 15632413
[TBL] [Abstract][Full Text] [Related]
23. Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes.
Harmes DC; Bresnick E; Lubin EA; Watson JK; Heim KE; Curtin JC; Suskind AM; Lamb J; DiRenzo J
Oncogene; 2003 Oct; 22(48):7607-16. PubMed ID: 14576823
[TBL] [Abstract][Full Text] [Related]
24. Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE/CHR tandem element and is downregulated by p53 but not by p63 or p73.
Rother K; Li YY; Tschöp K; Kirschner R; Müller GA; Mössner J; Engeland K
Cell Cycle; 2007 Apr; 6(7):853-62. PubMed ID: 17377499
[TBL] [Abstract][Full Text] [Related]
25. Solution structure and binding specificity of the p63 DNA binding domain.
Enthart A; Klein C; Dehner A; Coles M; Gemmecker G; Kessler H; Hagn F
Sci Rep; 2016 May; 6():26707. PubMed ID: 27225672
[TBL] [Abstract][Full Text] [Related]
26. p63 establishes epithelial enhancers at critical craniofacial development genes.
Lin-Shiao E; Lan Y; Welzenbach J; Alexander KA; Zhang Z; Knapp M; Mangold E; Sammons M; Ludwig KU; Berger SL
Sci Adv; 2019 May; 5(5):eaaw0946. PubMed ID: 31049400
[TBL] [Abstract][Full Text] [Related]
27. Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships.
Mantovani F; Zannini A; Rustighi A; Del Sal G
Biochim Biophys Acta; 2015 Oct; 1850(10):2048-60. PubMed ID: 25641576
[TBL] [Abstract][Full Text] [Related]
28. ChIP (chromatin immunoprecipitation) analysis demonstrates co-ordinated binding of two transcription factors to the promoter of the p53 tumour-suppressor gene.
Polson A; Takahashi P; Reisman D
Cell Biol Int; 2010 Sep; 34(9):883-91. PubMed ID: 20446924
[TBL] [Abstract][Full Text] [Related]
29. [TUMOR SUPPRESSOR p63 REGULATES EXPRESSION OF UBIQUITIN LIGASE Pirh2].
Daks AA; Petukhov AV; Shuvalov OY; Vasilieva EA; Melino G; Barlev NA; Fedorova OA
Tsitologiia; 2015; 57(12):876-9. PubMed ID: 26995965
[TBL] [Abstract][Full Text] [Related]
30. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome.
Neilsen PM; Noll JE; Suetani RJ; Schulz RB; Al-Ejeh F; Evdokiou A; Lane DP; Callen DF
Oncotarget; 2011 Dec; 2(12):1203-17. PubMed ID: 22203497
[TBL] [Abstract][Full Text] [Related]
31. Characterization of genome-wide p53-binding sites upon stress response.
Smeenk L; van Heeringen SJ; Koeppel M; van Driel MA; Bartels SJ; Akkers RC; Denissov S; Stunnenberg HG; Lohrum M
Nucleic Acids Res; 2008 Jun; 36(11):3639-54. PubMed ID: 18474530
[TBL] [Abstract][Full Text] [Related]
32. ΔNp63α Transcriptionally Regulates the Expression of CTEN That Is Associated with Prostate Cell Adhesion.
Yang K; Wu WM; Chen YC; Lo SH; Liao YC
PLoS One; 2016; 11(1):e0147542. PubMed ID: 26784942
[TBL] [Abstract][Full Text] [Related]
33. p63 cooperates with CTCF to modulate chromatin architecture in skin keratinocytes.
Qu J; Yi G; Zhou H
Epigenetics Chromatin; 2019 Jun; 12(1):31. PubMed ID: 31164150
[TBL] [Abstract][Full Text] [Related]
34. ΔNp63α represses anti-proliferative genes via H2A.Z deposition.
Gallant-Behm CL; Ramsey MR; Bensard CL; Nojek I; Tran J; Liu M; Ellisen LW; Espinosa JM
Genes Dev; 2012 Oct; 26(20):2325-36. PubMed ID: 23019126
[TBL] [Abstract][Full Text] [Related]
35. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
Gunaratne PH; Pan Y; Rao AK; Lin C; Hernandez-Herrera A; Liang K; Rait AS; Venkatanarayan A; Benham AL; Rubab F; Kim SS; Rajapakshe K; Chan CK; Mangala LS; Lopez-Berestein G; Sood AK; Rowat AC; Coarfa C; Pirollo KF; Flores ER; Chang EH
Cancer; 2019 Jul; 125(14):2409-2422. PubMed ID: 31012964
[TBL] [Abstract][Full Text] [Related]
36. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells.
Kim TK; Lee JS; Oh SY; Jin X; Choi YJ; Lee TH; Lee Eh; Choi YK; You S; Chung YG; Lee JB; DePinho RA; Chin L; Kim H
Cancer Res; 2007 Dec; 67(23):11133-40. PubMed ID: 18056437
[TBL] [Abstract][Full Text] [Related]
37. Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family.
Kehrloesser S; Osterburg C; Tuppi M; Schäfer B; Vousden KH; Dötsch V
Cell Death Differ; 2016 Dec; 23(12):1952-1960. PubMed ID: 27447112
[TBL] [Abstract][Full Text] [Related]
38. Evolutionary re-wiring of p63 and the epigenomic regulatory landscape in keratinocytes and its potential implications on species-specific gene expression and phenotypes.
Sethi I; Gluck C; Zhou H; Buck MJ; Sinha S
Nucleic Acids Res; 2017 Aug; 45(14):8208-8224. PubMed ID: 28505376
[TBL] [Abstract][Full Text] [Related]
39. The muscle regulatory transcription factor MyoD participates with p53 to directly increase the expression of the pro-apoptotic Bcl2 family member PUMA.
Harford TJ; Kliment G; Shukla GC; Weyman CM
Apoptosis; 2017 Dec; 22(12):1532-1542. PubMed ID: 28918507
[TBL] [Abstract][Full Text] [Related]
40. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C
Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
